Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs

The synthesis of a novel series of lamivudine prodrugs involving N4- substitution with isatin derivatives is described. The in-vitro antiretroviral activities indicated that compound 3b was found to be equipotent to lamivudine with EC50 of 0.0742 ± 0.04 μM. Lamivudine prodrugs bearing fluoroquinoles antibacterial showed 92-100% inhibition against Mycobacterium tuberculosis strain H37Rv at 6.25 μg ml-1. At pH 7.4, 37 °C, the hydrolytic t1/2 ranged between 120 and 240 min.